ADVANO is powering people’s lives with advanced battery technology. Founded in 2016, ADVANO has developed a next-generation silicon technology for Lithium-ion batteries. ADVANO utilizes earth-abundant raw materials and a sustainable and scalable manufacturing process to create high-performance silicon anode materials. Located in New Orleans, LA, ADVANO is committed to accelerating American clean energy manufacturing. With ADVANO’s REALSi™ technology, electric vehicles can drive further, consumer electronics can last longer, and the US can enable the electrification of everything.

Anagram is making vision care more affordable and accessible for providers and consumers. Thousands of eye care practices use Anagram to operate independently, process out-of-network benefits, and deliver better pricing on eyewear for their patients.

Arable, the leader in crop intelligence, advances digital agriculture globally. Forward-thinking agribusinesses, farming operations, and food and beverage companies use Arable to be more productive, sustainable, and profitable. Arable’s intuitive IoT-based solution combines reliable in-field weather, forecast, plant, soil, and irrigation data with advanced modeling and machine learning to deliver real-time, actionable insights into the entire crop system. Arable helps customers around the globe optimize water use, crop protection, fertilization, field work, research trials, food supply chains, and sustainability initiatives.

Astranis is a developer of a new satellite technology that aims to transmit data down to specific terrestrial locations with each satellite it launches. The company's mission is to help get online the 4 billion people who are without internet access. It was founded in 2015 and is headquartered in San Francisco, California.

At Atom Computing, we’re our customers’ biggest fans on the journey of discovery. That’s why we’re obsessed with creating the world’s most scalable and reliable quantum computers—giving them the power to develop breakthroughs that change the world.

Developer of electric propulsion orbital transfer vehicles. The company's vehicles rendezvouses with customer payloads in easily accessible, affordable low orbits along with disposal of defunct satellites through deorbiting or removal to a graveyard orbit, enabling space transportation companies to access their spacecraft to move satellites and other assets between orbits and to other destinations.

Our mission is to transform the heating & cooling of buildings, using geothermal energy to radically reduce costs for people and the environment.

Bigfinite's goal is to be the global partner in providing simple solutions to the analysis and control complex needs of industrial processes in Biotech and Pharma, covering all the supply chain, from R+D to patient dispensing. By offering a SAAS application for industrial use, under the philosophy of “Internet of Things”, that can be quickly implemented, without having to adapt or change the currently existing systems and with a customer ROI under six months. With efficiency, collaboration, interdisciplinary, joy, respect, transparency & commitment.

Cantos Ventures is a pre-seed and seed-stage venture capital fund that invests in startups in 'pre-inflection' industries. We view every startup as a journey, and seek to join those with noble aims.

CATALOG is a developer of a data conversion and storage platform used to offer the next generation of digital data archives and computation. Its platform facilitates the encoding of data and information into DNA format and makes it economically attractive to use DNA as the major medium for long-term archival of data that enables customers to store digital information in DNA molecules. It brings cutting-edge synthetic biology technologies to the world of information storage and computation.

Character Biosciences (formerly Clover Therapeutics) is a precision medicine platform that is unlocking the patterns of age-related diseases in people of diverse backgrounds. Our mission is to use human genetics to understand what drives diseases so we can discover targeted therapies to more effectively treat patients - many of whom lack any treatment options today. Character partners with patients, providers, payers, and scientists to create deeply-phenotyped patient cohorts to enable clinical genomic research. Our approach integrates genomics, longitudinal clinical and imaging data, machine learning, and novel experimental approaches to identify the molecular drivers of disease progression and develop innovative targeted medicines.

We are excited to announce that Clara Health has been acquired by M&B Sciences, a mission-aligned and strategic partner in the clinical research space. We strongly believe that by merging with M&B, we are able to make a greater difference in how patients experience clinical trials and contribute to breakthrough research.